Ones To Watch News
Refine Search
Biotechnology
Former Forbion partner Juliette Audet has been appointed chief business officer (CBO) at Netherlands-based NewAmsterdam Pharma Company. 3 April 2024
Pharmaceutical
A start-up company focused on digital health has launched with a series A financing round worth $20 million. 3 April 2024
Biotechnology
Shares in Gritstone bio, a US biotech that claims to be developing the world’s most potent vaccines, closed Tuesday’s trading nearly 49% lower. 3 April 2024
Biotechnology
French drugmaker Ipsen and US drug developer Sutro Biopharma have entered into an exclusive global licensing agreement for the antibody-drug conjugate (ADC) STRO-003. 3 April 2024
Pharmaceutical
Shares of US neurological drug specialist Acorda Therapeutics fell more than 81% to $2.50 by close on Monday after the company said it had filed for bankruptcy protection. 3 April 2024
Pharmaceutical
A start-up focused on neurology, Neurosterix, has launched with a $63 million series A financing led by Perceptive Xontogeny Venture Fund II. 3 April 2024
Biotechnology
BioInvent International announced a clinical trial collaboration and supply agreement with MSD International Business. 3 April 2024
Biotechnology
USA and UK-based cancer cell therapy developer Adaptimmune Therapeutics today announced that prestigious peer reviewed journal The Lancet has published the company's pivotal Phase II data with afamitresgene autoleucel (afami-cel. 2 April 2024
Biotechnology
Switzerland-based Roivant Sciences and Priovant Therapeutics today announced positive results from the Phase II study (NEPTUNE) evaluating brepocitinib in non-anterior non-infectious uveitis (NIU), showing the strongest efficacy data in NIU observed to date. 2 April 2024
Pharmaceutical
A new collaboration has been agreed between Israel’s Teva Pharmaceutical and Launch Therapeutics, related to the candidate TEV-248, which combines fluticasone and albuterol. 2 April 2024
Biotechnology
US clinical-stage biotech Zura Bio on Thursday announced the appointment of Robert Lisicki as chief executive (CEO), effective April 8, 2024. 29 March 2024
Pharmaceutical
The US Food and Drug Administration (FDA) has extended the review period for the New Drug Application (NDA) for govorestat (AT-007) as a treatment of classic galactosemia by three months. 29 March 2024
Biotechnology
US biotech major Gilead Sciences today announced an exclusive license agreement with Xilio Therapeutics to develop and commercialize Xilio’s Phase I tumor-activated interleukin (IL)-12 program, XTX301. 28 March 2024
Pharmaceutical
The US Food and Drug Administration (FDA) has approved Vafseo (vadadustat) tablets for the treatment of anemia due to chronic kidney disease (CKD) in adults who have been receiving dialysis for at least three months. 28 March 2024
Pharmaceutical
US biopharma Altimmune has claimed that it could have something special on its hands in the highly lucrative obesity field. 28 March 2024
Biotechnology
Dutch contract development and manufacturing organization (CDMO) Intravacc and Primrose Bio, a private US biotech developing discovery and production systems for protein and nucleic acid medicines, have announced a strategic partnership. 28 March 2024
Biotechnology
US biotech bluebird bio revealed that it had made mistakes in previous financial statements in a filing with the US Securities and Exchange Commission. 27 March 2024
Biotechnology
California, USA-based clinical-stage biopharmaceutical company 89bio saw its shares gain more than 2% to $11.44 today, after it announced that the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) status to pegozafermin in patients with metabolic-associated steatohepatitis (MASH). 27 March 2024
Biotechnology
A South Korean clinical stage biotech, Bridge Biotherapeutic), has entered into a research collaboration with the University of Colorado School of Medicine. 27 March 2024
Biotechnology
USA-based Praxis Precision Medicines, a biopharma translating genetic insights into therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, closed 21% up after Tuesday’s trading. 27 March 2024
Biotechnology
BioAge Labs today announced a multi-year research collaboration with Swiss pharma giant Novartis, with the news pushing the US biotech’s shares up 6.1% to $4.35 by early afternoon. 18 December 2024
Pharmaceutical
Marking its second deal this month alone, Novo Nordisk has entered into a multi-year collaboration with Massachusetts, USA-based Photys Therapeutics to develop novel proximity-based therapeutics for a cardiometabolic disease target. 18 December 2024
Biotechnology
Cara Therapeutics and Tvardi Therapeutics have announced a definitive agreement to merge, creating a new entity under the Tvardi name. 18 December 2024
Pharmaceutical
SiteOne Therapeutics has announced the completion of a $100 million series C financing, led by Novo Holdings, with participation from OrbiMed, Wellington Management, Mission BioCapital, and others. 18 December 2024
Biotechnology
Flagship Pioneering-founded genome engineering biotech Tessera Therapeutics today announced an investment of up to $50 million from the Bill & Melinda Gates Foundation to develop curative, globally accessible in vivo genetic therapies for sickle cell disease. 18 December 2024
Biotechnology
San Francisco-based Indapta Therapeutics, a privately held start-up developing next-generation cell therapies, has raised $22.5 million in a new financing round. The firm raised over $50 million in series A funding in 2022. 18 December 2024
Biotechnology
French CNS specialist Theranexus saw its shares leap more than 34% to 0.65 euros as it revealed a license and supply agreement with Exeltis to commercialize TX01, its novel formulation of a compound already approved in the indication for the treatment of rare neurological diseases. 18 December 2024
Biotechnology
Shares in US biopharma Viridian Therapeutics shot up by 21% on Monday. 17 December 2024
Biotechnology
US antivirals giant Gilead Sciences today revealed it has entered into a strategic collaboration to discover and develop novel, small molecule therapies across multiple targets with Californian biotech Terray Therapeutics. 17 December 2024
Pharmaceutical
Swedish biotech company Inify Laboratories has raised approximately 135 million kroner ($12.3 million) through a private placement, supporting a planned expansion into the UK. 16 December 2024
Biotechnology
Dewpoint Therapeutics and ConcertAI have announced the first phase of their translational oncology partnership, aligned around the former company's latest drug candidate, DPTX3186. 16 December 2024
Biotechnology
Bicycle Therapeutics, a UK-headquartered pharma company developing a new class of therapeutics based on its proprietary bicyclic peptide technology, closed a third lower on Friday. 16 December 2024
Biotechnology
In a filing with the US financial regulator, German mRNA specialist BioNTech has noted the lifting of a partial clinical hold on its PRESERVE-003 trial. 16 December 2024
Biotechnology
VectorY Therapeutics, a Netherlands-based biotech focused on neurodegenerative diseases, has appointed Jim Scibetta as chief executive officer. 16 December 2024
Biotechnology
Sino-American biotech BeiGene has announced it has entered into a global licensing agreement with China’s CSPC Zhongqi Pharmaceutical Technology for SYH2039, a novel methionine adenosyltransferase 2A (MAT2A)-inhibitor being explored for solid tumors. 13 December 2024
Pharmaceutical
US biotech Corcept Therapeutics has reported positive results from the Phase IV CATALYST study of Korlym (mifepristone) in people with hypercortisolism and difficult-to-control type 2 diabetes. 13 December 2024
Biotechnology
Nine months out from landing an additional $35 million in seed funding, Relation has more news – a big pharma collaboration. The group has announced a $45 million upfront deal, including a $15 million equity investment with UK pharma group GSK. 13 December 2024
Pharmaceutical
UK-based Tenpoint Therapeutics and Seattle’s Visus Therapeutics have announced the completion of their merger to create an entirely new chapter in ophthalmic therapeutic medicines aimed at rejuvenating the aging eye. 12 December 2024
Biotechnology
AI-driven biotech BenevolentAI has announced sweeping changes aimed at refocusing its operations and extending its financial runway into 2027. 12 December 2024
Biotechnology
USA-based Elevation Oncology, an innovative oncology company focused on the discovery and development of selective cancer therapies, has entered into a licensing agreement with Synaffix, part of Swiss out-sourcing major Lonza. 12 December 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze